China Shineway Pharmaceutical Group Resultados de beneficios anteriores

Pasado controles de criterios 4/6

China Shineway Pharmaceutical Group ha aumentado sus beneficios a una tasa media anual de 20.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 12.9% anual. Los ingresos han ido creciendo a una tasa media de 13.4% al año. La rentabilidad financiera de China Shineway Pharmaceutical Group es de 15.1%, y sus márgenes netos son de 26.3%.

Información clave

20.8%

Tasa de crecimiento de los beneficios

21.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	13.4%
Rentabilidad financiera	15.1%
Margen neto	26.3%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero China Shineway Pharmaceutical Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:C1S Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 24	4,205	1,105	2,111	107
31 Mar 24	4,361	1,037	2,212	109
31 Dec 23	4,517	970	2,314	110
30 Sep 23	4,525	926	2,318	124
30 Jun 23	4,534	883	2,323	137
31 Mar 23	4,242	803	2,215	127
31 Dec 22	3,951	723	2,107	117
30 Sep 22	3,718	651	2,004	117
30 Jun 22	3,485	579	1,902	116
31 Mar 22	3,354	568	1,832	115
31 Dec 21	3,224	557	1,763	113
30 Sep 21	3,122	453	1,676	109
30 Jun 21	3,020	350	1,590	105
31 Mar 21	2,838	322	1,528	102
31 Dec 20	2,656	295	1,466	100
30 Sep 20	2,592	382	1,425	88
30 Jun 20	2,528	469	1,384	77
31 Mar 20	2,617	486	1,393	90
31 Dec 19	2,706	503	1,402	103
30 Sep 19	2,670	520	1,367	102
30 Jun 19	2,633	537	1,332	100
31 Mar 19	2,602	521	1,293	114
31 Dec 18	2,570	506	1,254	128
30 Sep 18	2,492	516	1,174	136
30 Jun 18	2,413	526	1,095	144
31 Mar 18	2,166	489	929	120
31 Dec 17	1,920	452	763	97
30 Sep 17	1,897	474	708	81
30 Jun 17	1,873	496	653	66
31 Mar 17	1,933	542	651	70
31 Dec 16	1,993	589	648	74
30 Sep 16	1,935	569	659	79
30 Jun 16	1,877	549	669	84
31 Mar 16	1,966	603	673	76
31 Dec 15	2,055	658	678	69
30 Sep 15	2,147	672	691	73
30 Jun 15	2,239	685	705	78
31 Mar 15	2,234	695	701	79
31 Dec 14	2,229	705	697	80
30 Sep 14	2,228	704	697	79
30 Jun 14	2,227	703	698	78
31 Mar 14	2,207	693	699	81
31 Dec 13	2,187	684	701	83

Ingresos de calidad: C1S tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (26.3%) de C1S son superiores a los del año pasado (19.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lC1S han crecido significativamente en un 20.8% al año.

Acelerando crecimiento: El crecimiento de los beneficios de C1S en el último año (25.1%) supera su media de 5 años (20.8% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de C1S en el último año (25.1%) no superó al de la industria Pharmaceuticals 28.7%.

China Shineway Pharmaceutical Group Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: EPS: CN¥0.83 (vs CN¥0.65 in 1H 2023)

China Shineway Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.65 (vs CN¥0.44 in 1H 2022)

Recent updates

Investor sentiment improves as stock rises 16%

First half 2024 earnings released: EPS: CN¥0.83 (vs CN¥0.65 in 1H 2023)

China Shineway Pharmaceutical Group Limited Announces Second Interim Dividend in Respect of the Fiscal Year Ending December 31, 2024, Payable on September 27, 2024

China Shineway Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

Upcoming dividend of HK$0.46 per share

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 17%

China Shineway Pharmaceutical Group Limited Announces Resignation of Liu Tiejun as Executive Director, Effective 1 November 2023

Upcoming dividend of HK$0.12 per share at 5.9% yield

First half 2023 earnings released: EPS: CN¥0.65 (vs CN¥0.44 in 1H 2022)

China Shineway Pharmaceutical Group Limited Proposes Second Interim Dividend in Respect of the Fiscal Year 2023, Payable on 29 September 2023

China Shineway Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.74 in FY 2021)

Upcoming dividend of HK$0.35 per share at 5.6% yield

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.74 in FY 2021)

Less than half of directors are independent

China Shineway Pharmaceutical Group Limited Announces Board Changes

China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes

Upcoming dividend of HK$0.13 per share

First half 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.41 in 1H 2021)

China Shineway Pharmaceutical Group Limited Announces Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022

China Shineway Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.39 in FY 2020)

Upcoming dividend of HK$0.26 per share

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 27, 2022

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.39 in FY 2020)

Shineway Pharmaceutical Group Limited Resolves to Declare Interim Dividend of the Year Ending 31 December 2022, Payable on 18 May 2022

First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 1H 2020)

Investor sentiment improved over the past week

Upcoming dividend of HK$0.25 per share

Full year 2020 earnings released: EPS CN¥0.39 (vs CN¥0.64 in FY 2019)

China Shineway Pharmaceutical Group Limited Proposes Final Dividend, Payable on 17 June 2021

Full year 2020 earnings released: EPS CN¥0.39 (vs CN¥0.64 in FY 2019)

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: €0.65

New 90-day high: €0.60

New 90-day high: €0.58

China Shineway Pharmaceutical Group Limited Announces Committees Appointment

New 90-day low: €0.54

First half earnings released

First half earnings released

China Shineway Pharmaceutical Group Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - €0.55

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado